RBC Capital analyst Adnan Butt weighed in with some commentary on Aerie Pharmaceuticals Inc (NASDAQ:AERI) following an FDA agreement that the company may change the primary endpoint …
In a research report released April 30, Brean Capital analyst Difei Yang reiterated a Buy rating on Aerie Pharmaceuticals Inc (NASDAQ:AERI) with a $24 price …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) shares plunged nearly 64% today after the company reported disappointing efficacy results from its first Phase 3 trial for Rhopressa, the company’s lead glaucoma …
In a research report issued Friday, Brean Capital analyst Difei Yang reiterated a Buy rating on Aerie Pharmaceuticals Inc (NASDAQ:AERI), and reduced the price target …
In a research report published Friday, Cantor analyst Caroline Corner downgraded shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI), and significantly reduced the price target to $12.00 (from $40), …
